New Zealand approval for Botox in DHB hospitals

26 January 2017
pharmac-big

New Zealand’s Pharmaceutical Management Agency PHARMAC has announce the approval of an agreement with the local subsidiary of Ireland-incorporated drugmaker Allergan (NYSE: AGN) to amend the contractual terms of listing for clostridium botulinum type A toxin ( Botox (external link) ),  inj 100 u vial in DHB hospitals.

Botox is used to treat medical conditions associated with overactive muscles including

overactive bladder with leakage of urine (urinary incontinence).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical